Investment
Features
FeesSafety
Academy
More
Pluang+

Miivo AI hires RMK Marketing for $500K online marketing campaign, pending TSXV approval

Company Fundamentals
19 Oct 2026
Newsfile Corp
View Source
Bullish
Miivo AI hires RMK Marketing for $500K online marketing campaign, pending TSXV approval

Miivo AI Inc. has signed a six-month contract with RMK Marketing Inc. to provide online marketing and investor relations services, with a total budget of CAD$500,000. The campaign includes digital ads, advertorials, and investor awareness efforts, subject to approval by the TSX Venture Exchange. The agreement emphasizes cash payments only, no equity compensation, and allows termination with 30 days' notice. This marketing push aims to boost Miivo's visibility as it advances its AI-powered platform for small and medium-sized businesses.

Miivo's marketing services agreement with RMK Marketing is presented here with a snapshot of the Technology sector on Pluang as of Oct 20, 2026 03:01 WIB. Among 150 priced US tech stocks, 81 rose and 67 fell. Notably, Fortinet Inc (FTNT) dropped 7.10% to USD 169.00 with 74% of orders selling and a typical hold time of 72 days, contrasting with Cloudflare Inc (NET) which rose by 100% buy order activity despite a 6.97% price decline to USD 294.11. Zscaler Inc (ZS) also fell 7.05% to USD 204.88 with 83% sell orders and a shorter hold time of 42 days.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App